TY - JOUR
T1 - Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia
AU - Hayashi, Meiso
AU - Denjoy, Isabelle
AU - Extramiana, Fabrice
AU - Maltret, Alice
AU - Buisson, Nathalie Roux
AU - Lupoglazoff, Jean Marc
AU - Klug, Didier
AU - Hayashi, Miyuki
AU - Takatsuki, Seiji
AU - Villain, Elisabeth
AU - Kamblock, Joël
AU - Messali, Anne
AU - Guicheney, Pascale
AU - Lunardi, Joël
AU - Leenhardt, Antoine
PY - 2009/5/12
Y1 - 2009/5/12
N2 - Background - The pathophysiological background of catecholaminergic polymorphic ventricular tachycardia is well understood, but the clinical features of this stress-induced arrhythmic disorder, especially the incidence and risk factors of arrhythmic events, have not been fully ascertained. Methods and Results - The outcome in 101 catecholaminergic polymorphic ventricular tachycardia patients, including 50 probands, was analyzed. During a mean follow-up of 7.9 years, cardiac events defined as syncope, aborted cardiac arrest, including appropriate discharges from implantable defibrillators, or sudden cardiac death occurred in 27 patients, including 2 mutation carriers with normal exercise tests. The estimated 8-year event rate was 32% in the total population and 27% and 58% in the patients with and without β-blockers, respectively. Absence of β-blockers (hazard ratio [HR], 5.48; 95% CI, 1.80 to 16.68) and younger age at diagnosis (HR, 0.54 per decade; 95% CI, 0.33 to 0.89) were independent predictors. Fatal or near-fatal events defined as aborted cardiac arrest or sudden cardiac death occurred in 13 patients, resulting in an estimated 8-year event rate of 13%. Absence of β-blockers (HR, 5.54; 95% CI, 1.17 to 26.15) and history of aborted cardiac arrest (HR, 13.01; 95% CI, 2.48 to 68.21) were independent predictors. No difference was observed in cardiac and fatal or near-fatal event rates between probands and family members. Conclusions - Cardiac and fatal or near-fatal events were not rare in both catecholaminergic polymorphic ventricular tachycardia probands and affected family members during the long-term follow-up, even while taking β-blockers, which was associated with a lower event rate. Further studies evaluating concomitant therapies are necessary to improve outcome in these patients.
AB - Background - The pathophysiological background of catecholaminergic polymorphic ventricular tachycardia is well understood, but the clinical features of this stress-induced arrhythmic disorder, especially the incidence and risk factors of arrhythmic events, have not been fully ascertained. Methods and Results - The outcome in 101 catecholaminergic polymorphic ventricular tachycardia patients, including 50 probands, was analyzed. During a mean follow-up of 7.9 years, cardiac events defined as syncope, aborted cardiac arrest, including appropriate discharges from implantable defibrillators, or sudden cardiac death occurred in 27 patients, including 2 mutation carriers with normal exercise tests. The estimated 8-year event rate was 32% in the total population and 27% and 58% in the patients with and without β-blockers, respectively. Absence of β-blockers (hazard ratio [HR], 5.48; 95% CI, 1.80 to 16.68) and younger age at diagnosis (HR, 0.54 per decade; 95% CI, 0.33 to 0.89) were independent predictors. Fatal or near-fatal events defined as aborted cardiac arrest or sudden cardiac death occurred in 13 patients, resulting in an estimated 8-year event rate of 13%. Absence of β-blockers (HR, 5.54; 95% CI, 1.17 to 26.15) and history of aborted cardiac arrest (HR, 13.01; 95% CI, 2.48 to 68.21) were independent predictors. No difference was observed in cardiac and fatal or near-fatal event rates between probands and family members. Conclusions - Cardiac and fatal or near-fatal events were not rare in both catecholaminergic polymorphic ventricular tachycardia probands and affected family members during the long-term follow-up, even while taking β-blockers, which was associated with a lower event rate. Further studies evaluating concomitant therapies are necessary to improve outcome in these patients.
KW - Beta-blocker
KW - Clinical genetics
KW - Death
KW - Follow-up studies
KW - Mutation
KW - Sudden
KW - Tachycardia
KW - Ventricular
UR - http://www.scopus.com/inward/record.url?scp=66549094345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66549094345&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.108.829267
DO - 10.1161/CIRCULATIONAHA.108.829267
M3 - Article
C2 - 19398665
AN - SCOPUS:66549094345
SN - 0009-7322
VL - 119
SP - 2426
EP - 2434
JO - Circulation
JF - Circulation
IS - 18
ER -